Article
FDA Grants EUA to COVID-19 Antibody Test That Can Assess Symptom Severity
Author(s):
COVID-19 antibody test may also be able to identify those who have been exposed to the disease but have so far been asymptomatic.
The FDA has granted an Emergency Use Authorization (EUA) to a novel coronavirus disease 2019 (COVID-19) antibody test that is able to determine the severity of an individual’s symptoms. The test was developed by Vibrant American Clinical Labs, a leading science and technology company, and tested by investigators from the University of Denver’s Knoebel Institute for Healthy Aging and Resilience Code, a functional medicine and human performance clinic.
“This antibody test has more test points than others that have been approved by the FDA,” Lotta Granholm-Bentley, the founding executive director of the Knoebel Institute and one of the project’s lead researchers said. “Other tests check for only a few viral antigens, whereas this one could test for as many as a dozen.”
Investigators discovered different profiles of antibodies between people who were positive with the virus and had mild or severe symptoms. Using this information from the test, they were able to predict the severity of their outcome.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
